HemoGenix, Inc

02/18/2026

Cytokine Release Assays are crucial for assessing immunotoxicity in drug development. At HemoGenix, we utilize various culture formats and advanced flow cytometry to analyze cytokine release. These assays help predict inflammatory responses, ensuring the safety of new therapies. Explore our capabilities and learn how we can support your research.

Email from HemoGenix Inc.   Cytokine Release Assays Immunotoxicity represents a diverse set of studies that includes Cytokine Release Assays (CRAs) to understanding whether a new drug candidate will e

01/20/2026

Early Assessment of Drug Safety Profiles
Contract Research Services

Early assessment of drug safety profiles is a critical component of the drug development process. Detecting potential toxicities at the very beginning of the drug discovery pipeline helps prevent significant downstream problems, especially those that may arise during clinical trials. This proactive approach is vital to ensure that a preclinical candidate is suitable for continued development and long-term success.

Learn more: https://conta.cc/3NtdC8q

01/15/2026

In Vitro Hematotoxicity Testing: Advancements and Capabilities

In vitro hematotoxicity testing represents one of the most established areas within toxicology research, with a robust foundation that dates back to the 1960s. This long-standing discipline has been instrumental in the development of reliable methods for assessing the toxicity effects on blood and blood-forming tissues.

Learn more: https://conta.cc/4b10GR4

12/02/2025

Early Assessment of Drug Safety Profiles

Early in vitro toxicity detection plays a critical role in the drug development process. Identifying potential toxicities at the onset of the drug discovery pipeline can prevent numerous downstream issues, particularly during clinical trials. This early assessment is essential to confirm that a preclinical candidate is viable for further development and long-term success.

Learn more: https://conta.cc/44JGLln

11/13/2025

HALO®-Tox HT: A Revolutionary Platform in Stem Cell and Bone Marrow Toxicity Testing

HALO®-Tox HT is a proprietary, fully standardized, high-throughput toxicity assay platform that has been validated according to FDA Bioanalytical Method Validation Guidelines. It incorporates two technologies:

> Suspension Expansion Culture™ (SEC™) Technology
> ATP Bioluminescence Technology

Learn more: https://www.hemogenix.com/Hemotoxicity.php

10/28/2025

Mesenchymal Cell System Toxicity

MSCGlo™-Tox HT is a fully standardized and validated ATP bioluminescence toxicity assay that measures functional viability of cells based on intracellular ATP (iATP) concentrations. MSCGlo™-Tox HT is a metabolic viability assay designed specifically for MSCs.

Learn more: https://hemogenix.com/MSC_Toxicity.php

10/02/2025

In Vitro Toxicology
Early Assessment of Drug Safety Profiles

Learn more: https://conta.cc/489WFs6

09/23/2025

Neurotoxicity Screening and Testing

Most in vitro neurotoxicity studies are performed on human iPS-derived cells in pre-coated 96- or 384-well plates. The assay platform used is called NeuroGlo™-Tox HT and is a proprietary assay based originally on the HemoGenix® HALO® Platform for stem and progenitor cell hematotoxicity screening and testing. Like the HALO® Platform, NeuroGlo™-Tox HT incorporates the most sensitive non-radioactive signal detection system available, namely ATP bioluminescence.

Learn more: https://hemogenix.com/Neurotoxicity.php

09/10/2025

In Vitro to In Vivo Concordance

Learn more: https://conta.cc/45QiGKV

08/21/2025

Eliminate the Potential of Pre-Clinical Surprises

Even with extensive measures taken to reduce unwanted and occasionally uninterpretable pre-clinical data, such issues may still arise, leading to substantial complications.

At HemoGenix®, our priority is to predict toxicity—particularly within the lympho-hematopoietic system- before unexpected pre-clinical results arise. When such challenges do occur, we are ready to support you as a trusted contract research partner.

Learn more: https://conta.cc/4oKCI0w

08/13/2025

In Vitro Primary Cell Toxicity Screening

Early in vitro screening of compounds against primary target cells can provide a wealth of information to help reduce drug development time and cost. When targeted to specific primary cell populations that might exhibit potential toxicity, such information early on in drug development, can be a game changer. In addition, in vitro assessment of drug combinations and the ability to compare toxicity profiles using the same readout, can significantly streamline the drug development process.

For more information, visit www.hemogenix.com or contact us directly at screening@hemogenix.com or by calling 719-264-6250. We look forward to assisting you.

07/30/2025

Immunotoxicity and Immune Cell Testing
https://conta.cc/41l74g2